OM
OMCL.US Omnicell Inc
- Market cap
- USD 1.61B
- P/E
- 36.5x
- P/B
- 1.22x
- ROE
- 4.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OMCL.US undervalued?
Graham numberOMCL.US trades 40.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Omnicell Inc fundamental analysis
No fundamental analysis for Omnicell Inc yet.
Omnicell Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automatio…
Full company profileOmnicell Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Omnicell Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 693M | 716M | 787M | 897M | 892M | 1.13B | 1.30B | 1.15B | 1.11B | 1.18B | 1.24B |
| Gross Profit | 314M | 322M | 372M | 437M | 413M | 555M | 589M | 497M | 471M | 508M | 575M |
| Operating Income | 6.48M | 5.75M | 44.4M | 78.4M | 35.5M | 89.5M | -2.32M | -34.9M | 337K | 11.7M | 85.6M |
| EBITDA | 64.8M | 62.7M | 95.7M | 142M | 107M | 173M | 96.8M | -34.9M | 120M | 102M | 166M |
| Net Income | 603K | 20.6M | 37.7M | 61.3M | 32.2M | 77.8M | 5.65M | -20.4M | 12.5M | 2.05M | 62.3M |
| EPS | 0.02 | 0.53 | 0.93 | 1.43 | 0.74 | 1.62 | 0.12 | -0.45 | 0.27 | 0.04 | 1.34 |
| Balance Sheet | |||||||||||
| Total Assets | 935M | 980M | 1.08B | 1.24B | 1.82B | 2.14B | 2.21B | 2.23B | 2.12B | 1.97B | 2.06B |
| Total Liabilities | 503M | 463M | 402M | 396M | 857M | 996M | 1.08B | 1.04B | 878M | 743M | 740M |
| Shareholders' Equity | 432M | 517M | 680M | 845M | 968M | 1.15B | 1.13B | 1.19B | 1.24B | 1.23B | 1.32B |
| Cash & Short-term Investments | 54.5M | 32.4M | 67.2M | 137M | 496M | 360M | 342M | 480M | 382M | 211M | 315M |
| Total Debt | 254M | 210M | 144M | 111M | 528M | 541M | 617M | 614M | 383M | 204M | 201M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 47.9M | 24.8M | 104M | 145M | 186M | 232M | 77.8M | 181M | 188M | 127M | 209M |
| Capital Expenditure | 29.2M | 30.5M | 54.4M | 61.7M | 54.9M | 29.0M | 60.7M | 41.5M | 36.5M | 40.4M | 43.7M |
| Free Cash Flow | 18.8M | -5.71M | 49.6M | 83.3M | 131M | 203M | 17.0M | 140M | 151M | 86.9M | 166M |
| Ratios | |||||||||||
| ROE | 0.1% | 4.0% | 5.6% | 7.3% | 3.3% | 6.8% | 0.5% | -1.7% | 1.0% | 0.2% | 4.7% |
| ROA | 0.1% | 2.1% | 3.5% | 4.9% | 1.8% | 3.6% | 0.3% | -0.9% | 0.6% | 0.1% | 3.0% |
| Net Profit Margin | 0.1% | 2.9% | 4.8% | 6.8% | 3.6% | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% | 5.0% |
| Debt to Equity | 0.59x | 0.41x | 0.21x | 0.13x | 0.55x | 0.47x | 0.55x | 0.52x | 0.31x | 0.17x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Omnicell Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 4.40M | 0.10 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 106M | 2.41 | 327.9% |
| 2019 | USD 9.67M | 0.23 | 15.8% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Omnicell Inc
- Insiders 2.25%
- Institutions 97.75%
- Public & others 0.00%
- Shares outstanding 46.0M
- Free float 44.8M
Top funds holding OMCL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.75M | 5.98% | +0.06% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.37M | 2.98% | 0.00% | Sep 2026 |
| Nomura Small Cap Core I | 1.16M | 2.53% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.16M | 2.52% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 976K | 2.12% | -1.74% | Sep 2026 |
| DFA U.S. Small Cap Value I | 873K | 1.90% | +39.69% | Sep 2026 |
| American Century Small Cap Growth Inv | 649K | 1.41% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 635K | 1.38% | +2.45% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 635K | 1.38% | +0.58% | Sep 2026 |
| Fidelity Small Cap Index | 500K | 1.09% | +0.14% | Aug 2026 |
| iShares Russell 2000 Value ETF | 432K | 0.94% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 417K | 0.91% | -0.05% | Oct 2026 |
| Vanguard Strategic Equity Inv | 398K | 0.86% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 393K | 0.85% | +0.27% | Oct 2026 |
| Global X Robotics & Artfcl Intllgnc ETF | 380K | 0.83% | -0.10% | Oct 2026 |
| iShares S&P Small-Cap 600 Value ETF | 377K | 0.82% | 0.00% | Oct 2026 |
| Touchstone Small Company A | 359K | 0.78% | 0.00% | Sep 2026 |
| Glenmede Small Cap Equity Adv | 286K | 0.62% | +35.31% | Sep 2026 |
| Dimensional US Small Cap Value ETF | 267K | 0.58% | +0.04% | Sep 2026 |
| Vanguard Russell 2000 ETF | 265K | 0.58% | +0.99% | Sep 2026 |
Top institutions holding OMCL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 7.54M | 16.39% | +4.61% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.15M | 6.85% | -1.97% | Jun 2026 |
| Wellington Management Company LLP | 2.70M | 5.87% | -0.24% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.56M | 5.56% | +4.33% | Sep 2026 |
| State Street Corp | 2.09M | 4.53% | +6.93% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.97M | 4.28% | +1.86% | Jun 2026 |
| Millennium Management LLC | 1.73M | 3.77% | -24.22% | Jun 2026 |
| Delaware Management Holdings Inc | 1.61M | 3.49% | +35.72% | Jun 2026 |
| Geode Capital Management, LLC | 1.22M | 2.65% | +6.49% | Jun 2026 |
| Nuveen, LLC | 1.03M | 2.24% | +164.74% | Jun 2026 |
| Acadian Asset Management LLC | 1.01M | 2.20% | +40.78% | Sep 2026 |
| American Century Companies Inc | 973K | 2.12% | +796.83% | Sep 2026 |
| Arrowstreet Capital Limited Partnership | 913K | 1.98% | +226.67% | Jun 2026 |
| Bank of America Corp | 901K | 1.96% | +55.07% | Jun 2026 |
| Two Sigma Investments LLC | 795K | 1.73% | -24.44% | Jun 2026 |
| Charles Schwab Investment Management Inc | 639K | 1.39% | -2.25% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 605K | 1.32% | -1.81% | Jun 2026 |
| Royal Bank of Canada | 574K | 1.25% | +7.90% | Jun 2026 |
| The Goldman Sachs Group Inc | 540K | 1.18% | +52.93% | Jun 2026 |
| Boston Partners Global Investors, Inc | 518K | 1.13% | -2.47% | Jun 2026 |
Omnicell Inc company profile
- Company name
- Omnicell Inc
- Ticker
- OMCL.US
- Exchange
- USA Stocks
- Listed since
- Aug 7, 2001
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 3,450
- Fiscal year end
- December
- Address
- 4220 North Freeway, Fort Worth, TX, United States, 76137
- Phone
- 877 415 9990
- Website
- omnicell.com
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Omnicell Inc management
10- Mr. Randall A. LippsFounder, Executive Chairman & CEO · born 1957
- Mr. Nnamdi N. NjokuPresident & COO · born 1977
- Mr. H. Baird Radford IIIExecutive VP & CFO · born 1970
- Mr. Corey J. Manley J.D.Executive VP, Chief Legal & Administrative Officer and Corporate Secretary · born 1978
- Mr. Brian H. NuttVP, Chief Accounting Officer & Corporate Controller · born 1970
- Dr. Perry A. Genova Ph.D.Senior VP & CTO
- Mr. David UngerVice President of Investor Relations
- Mr. Tomer StavitskySenior VP & Chief Corporate Development Officer
- Ms. Stella PrefachSenior VP & Chief Marketing Officer
- Mr. Dave FordSVP & Chief People Officer